Olomorasib Combo Elicits Favorable Efficacy in NSCLC
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated metastatic non–small cell lung cancer.
Related Articles
Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma
Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.
Annals of Oncology 35th Anniversary – Interview with Prof. David Kerr
Prof. Kerr discusses the challenges he faced, the journal’s evolution, and its growing impact on the field
Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy
Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.
Selinexor Shows Potential as Maintenance Therapy for TP53 Wild-Type, pMMR Endometrial Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses how selinexor may address the need for effective maintenance therapies in pMMR, TP53 wild-type endometrial cancer.
Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma
Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.
Finding the ‘Right Fit’ for ER+ Breast Cancer After Aromatase Inhibitor AEs
A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast cancer.
Cilta-Cel Shows ‘Promising Efficacy, Safety’ in Newly Diagnosed MM | Blood Cancers Today
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM who have had suboptimal response to frontline…
